Latest Breaking News On - Department of gastrointestinal medical oncology - Page 1 : comparemela.com

Bile Duct Cancer Continues to Respond to Zanidatamab, Per Longer Follow-Up

Zanidatamab continued to lead to responses and improved overall survival in pretreated HER2-positive biliary tract cancer.

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,.

Dr Halperin on the FDA Approval of Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETs

Bristol Myers: cancer treatment results -April 09, 2024 at 09:52 am EDT

Bristol Myers announces that KRAZATI in combination with cetuximab demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated locally advanced or.

Dr Overman on Nonoperative Cancer Management in GI Malignancies

Michael J. Overman, MD, discusses the rationale for utilizing a nonoperative management approach over traditional surgery in gastrointestinal cancers.